Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer.

Document types check

Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/29483

Title:	Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer.
Authors:	Blackhall, Fiona Ross Camidge, D Shaw, Alice T Soria, Jean-Charles Solomon, Benjamin J Mok, Tony Hirsh, Vera Jänne, Pasi A Shi, Yuankai Yang, Pan-Chyr Pas, Tommaso De Hida, Toyoaki Carpeño, Javier De Castro Lanzalone, Silvana Polli, Anna Iyer, Shrividya Reisman, Arlene Wilner, Keith D Kim, Dong-Wan View more
Keywords:	Alk clinical trial crizotinib profile 1005 View more
Issue Date:	2017
Citation:	ESMO Open.2017;(2)3:e000219
Abstract:	Crizotinib is a potent, orally administered tyrosine kinase inhibitor approved for the treatment of anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer (NSCLC). We report final results from PROFILE 1005, the largest clinical trial to date for an ALK inhibitor in ALK-positive NSCLC.
PMID:	29209525
URI:	https://hdl.handle.net/20.500.12530/29483
Rights:	openAccess
ISSN:	2059-7029
Appears in Collections:	Fundaciones e Institutos de Investigación > IIS H. U. La Paz > Artículos Hospitales > H. U. La Paz > Artículos

Files in This Item:

File	Description	Size	Format
PMC5703388.pdf		722.75 kB	Adobe PDF	View/Open